SCHEMBL5220630

SCHEMBL5220630

NC1CCN(c2cc(F)cc(F)c2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR2 P30874 10/20 0.44
BPTF Q12830 1/20 0.39
NPY5R Q15761 5/20 0.39
SSTR4 P31391 2/20 0.37
VCP P55072 1/20 0.37
MAOB P27338 1/20 0.37
HTR3E A5X5Y0 1/20 0.36
MEN1 O00255 1/20 0.36
HTR3B O95264 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
HTR3A P46098 1/20 0.36
KMT2A Q03164 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219506 0.83 SSTR2 (0.44) SSTR2
SCHEMBL29991273 0.81 BPTF (0.60) SSTR2BPTFNPY5RVCPHTR3E
SCHEMBL377392 0.81 BPTF (0.60) SSTR2BPTFNPY5RVCPHTR3E
Hydrochloric Acid SCHEMBL376509 0.80 BPTF (0.59) SSTR2BPTFNPY5RVCPHTR3E
SCHEMBL377434 0.79 ALDH1A1 (0.59) MEN1TSHRKMT2AHRH3
SCHEMBL25513241 0.79 NPY5R (0.42) BPTFNPY5RMAOBMEN1KMT2A
SCHEMBL18259210 0.79 BPTF (0.42) BPTFNPY5RMAOB
SCHEMBL6506081 0.77 ALDH1A1 (0.42) SSTR2NPY5RMEN1CYP1A2KMT2A
SCHEMBL14336833 0.75 CHRM2 (0.53) SSTR2NPY5RVCPHTR3EMEN1
SCHEMBL9831211 0.75 ALDH1A1 (0.44) MAOBMEN1ALOX15TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304076-B2 Neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION (US) 2007-12-04 US disclosed
US-7304076-B2 Neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION (US) 2007-12-04 US disclosed
EP-1399433-B1 FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2007-08-22 EP disclosed
US-7183290-B2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-02-27 US disclosed
US-20040242636-A1 Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity SMITHKLINE BEECHAM CORPORATION 2004-12-02 US disclosed
EP-1399433-A2 FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-03-24 EP disclosed
WO-2003002553-A2 FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242636-A1 Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity DPP4, DPP7, DPP3 SSTR2 2645/4885BPTF 3999/4885NPY5R 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.